Incidence of baseline prognostic factors in the high and low sIL-6r groups derived from the optimal 81.5 ng/mL cut point
| Prognostic factor . | sIL-6r level cut point . | P† . | |
|---|---|---|---|
| < 81.5 ng/mL, n/N* (%) . | ≥ 81.5 ng/mL, n/N* (%) . | ||
| Age, ≥ 65 y | 126/497 (25) | 41/129 (32) | .141 |
| Albumin < 3.5 g/dL | 155/494 (31) | 49/129 (38) | .154 |
| β2-microglobulin ≥ 3.5 mg/L | 211/493 (43) | 97/129 (75) | < .001 |
| β2-microglobulin ≥ 5.5 mg/L | 87/493 (18) | 65/129 (50) | < .001 |
| Creatinine ≥ 2 mg/dL | 32/493 (6) | 19/128 (15) | .002 |
| CRP ≥ 8 mg/L | 144/494 (29) | 40/129 (31) | .680 |
| Hemoglobin < 10 g/dL | 124/495 (25) | 70/129 (54) | < .001 |
| LDH ≥ 190 U/L | 85/495 (17) | 60/129 (47) | < .001 |
| Cytogenetic abnormalities | 155/492 (32) | 69/126 (55) | < .001 |
| GEP high-risk | 46/497 (9) | 35/129 (27) | < .001 |
| CD-1 subgroup | 33/497 (7) | 8/128 (6) | .874 |
| CD-2 subgroup | 81/497 (16) | 8/128 (6) | .004 |
| HY subgroup | 166/497 (33) | 30/128 (23) | .030 |
| LB subgroup | 42/497 (8) | 24/128 (19) | < .001 |
| MF subgroup | 19/497 (4) | 17/128 (13) | < .001 |
| MS subgroup | 64/497 (13) | 13/128 (10) | .404 |
| MY subgroup | 43/497 (9) | 7/128 (5) | .237 |
| PR subgroup | 49/497 (10) | 21/128 (16) | .036 |
| GEP proliferation index ≥ 10 | 36/497 (7) | 16/129 (12) | .058 |
| TP53 deletion | 88/497 (18) | 20/129 (16) | .555 |
| Prognostic factor . | sIL-6r level cut point . | P† . | |
|---|---|---|---|
| < 81.5 ng/mL, n/N* (%) . | ≥ 81.5 ng/mL, n/N* (%) . | ||
| Age, ≥ 65 y | 126/497 (25) | 41/129 (32) | .141 |
| Albumin < 3.5 g/dL | 155/494 (31) | 49/129 (38) | .154 |
| β2-microglobulin ≥ 3.5 mg/L | 211/493 (43) | 97/129 (75) | < .001 |
| β2-microglobulin ≥ 5.5 mg/L | 87/493 (18) | 65/129 (50) | < .001 |
| Creatinine ≥ 2 mg/dL | 32/493 (6) | 19/128 (15) | .002 |
| CRP ≥ 8 mg/L | 144/494 (29) | 40/129 (31) | .680 |
| Hemoglobin < 10 g/dL | 124/495 (25) | 70/129 (54) | < .001 |
| LDH ≥ 190 U/L | 85/495 (17) | 60/129 (47) | < .001 |
| Cytogenetic abnormalities | 155/492 (32) | 69/126 (55) | < .001 |
| GEP high-risk | 46/497 (9) | 35/129 (27) | < .001 |
| CD-1 subgroup | 33/497 (7) | 8/128 (6) | .874 |
| CD-2 subgroup | 81/497 (16) | 8/128 (6) | .004 |
| HY subgroup | 166/497 (33) | 30/128 (23) | .030 |
| LB subgroup | 42/497 (8) | 24/128 (19) | < .001 |
| MF subgroup | 19/497 (4) | 17/128 (13) | < .001 |
| MS subgroup | 64/497 (13) | 13/128 (10) | .404 |
| MY subgroup | 43/497 (9) | 7/128 (5) | .237 |
| PR subgroup | 49/497 (10) | 21/128 (16) | .036 |
| GEP proliferation index ≥ 10 | 36/497 (7) | 16/129 (12) | .058 |
| TP53 deletion | 88/497 (18) | 20/129 (16) | .555 |